The clearance of amyloid beta (Ab) from the brain represents a novel therapeutic target for Alzheimer's disease. Conflicting data exist regarding the contribution of adenosine triphosphatebinding cassette transporters to the clearance of Ab through the blood-brain barrier. Therefore, we investigated whether Ab could be a substrate for P-glycoprotein (P-gp) and/or for breast cancer resistance protein (BCRP) using a human brain endothelial cell line, hCMEC/D3. Inhibition of P-gp and BCRP increased apical-to-basolateral, but not basolateral-to-apical, permeability of hCMEC/D3 cells to 125 I Ab 1-40. Our in vitro data suggest that P-gp and BCRP might act to prevent the blood-borne Ab 1-40 from entering the brain.
Introduction
Increased levels of neurotoxic amyloid beta (Ab) peptides of 1-40 and 1-42 amino acids in length (Ab 1-40, 1-42) are thought to be central in the pathogenesis of Alzheimer's disease (AD) (Hardy, 2006) . A potential therapeutic treatment for AD is to increase the clearance of Ab from the brain thus, reducing the amyloid burden. Brain endothelial cells (BECs) at the blood-brain barrier (BBB) express multiple transporters for Ab, which lead to Ab influx into (RAGE (receptor for advanced glycation end products), megalin) and efflux from (LRP-1 (lowdensity lipoprotein receptor related protein)) the central nervous system (Zlokovic, 2008) . BECs also express the adenosine triphosphate-binding cassette efflux transporters, P-glycoprotein (P-gp), and the breast cancer resistance protein (BCRP), which have a similar substrate overlap, and act to prevent unwanted blood-borne signalling molecules from entering the brain (Loscher and Potschka, 2005) . P-gp has been recently described as a potential Ab transporter (Cirrito et al, 2005; Kuhnke et al, 2007; Lam et al, 2001) , although evidence is conflicting (Ito et al, 2006; Nazer et al, 2008) . To date, there have been no reported investigations regarding the inter-actions between Ab and P-gp or BCRP in human BECs in vitro. Therefore, we examined the role of each efflux transporter on Ab 1-40 transport using a physiologic concentration of 125 I Ab 1-40 in an immortalised human BEC line, hCMEC/D3 cells.
Materials and methods
Cell Culture hCMEC/D3 cells were cultured in EBM-2 medium (Lonza, Slough, Wokingham, UK), which was supplemented with vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), hydrocortisone, ascorbate, gentamycin, and 2.5% fetal bovine serum (FBS). hCMEC/D3 cells were cultured on collagen-coated (Sigma-Aldrich, Gillingham, Dorset, UK; 0.005% w/v, 1 h at room temperature) 24-well tissue culture plates in a humidified atmosphere at 371C in 5% CO 2 . For permeability experiments, transwell polyester membrane inserts (Corning Costar, High Wycombe, Buckinghamshire, UK; 0.4-mm pore, 12-mm diameter) were first coated with collagen and then with fibronectin (Sigma-Aldrich; 5 mg/mL, 1 h). hCMEC/D3 cells were grown to confluence (B1 Â 10 5 cells/cm 2 ) with a culture media change every 2 to 3 days and incubated for 2 days after confluence before treatment.
125
I Ab 1-40 Net Uptake by hCMEC/D3 Cells hCMEC/D3 cells were incubated for 0.5, 1, 3, or 24 h with 0.1 nmol/L 125 I Ab 1-40 (Bachem, Weil am Rheim, Germany; 1,110 Ci/mmol). For some experiments, hCMEC/ D3 cells were incubated for 30 mins with 0.1 nmol/L of 125 I Ab 1-40 and 2 mmol/L vinblastine (a competitive P-gp and multi-drug resistance protein-1 (MRP-1) inhibitor; Sigma-Aldrich), 300 nmol/L of tariquidar (a specific P-gp inhibitor; a kind gift from Xenova, Slough, Berkshire, UK), 2 mmol/L of fumitrimorgan C (FTC, a competitive BCRP inhibitor; Axxora, Nottingham, Nottinghamshire, UK), or a dimethyl sulfoxide (DMSO) vehicle control. For all samples, the 125 I Ab remaining in the media and in trypsinised hCMEC/D3 cells was measured using a g-counter (Wallac Wizard, Perkin Elmer, Cambridgeshire, UK). For these and for the subsequent experiments using 125 I Ab 1-40, culture media or whole cell lysates were precipitated with 15% trichloroacetic acid overnight at 41C, and radioactivity corresponding to free 125 I (B1 to 2%) was subtracted from total counts resulting in a measure of peptide-bound 125 I. The total amount of protein in each sample was determined using a DC protein assay (BioRad, Hemel Hempstead, Hertfordshire, UK) and the net uptake of 125 I Ab by hCMEC/D3 cells was related to the total amount of protein in cell suspension (fmol/mg).
I Ab 1-40 Efflux from hCMEC/D3 Cells hCMEC/D3 cells were preloaded with 0.1 nmol/L of 125 I Ab 1-40 for 3 h, the culture media removed, and the levels of 125 I Ab 1-40 counted. hCMEC/D3 cells were incubated in a fresh culture medium containing 300 nmol/L of tariquidar, 2 mmol/L vinblastine, 2 mmol/L FTC, or vehicle alone for 7.5, 15, 30, 60, or 180 mins at 371C. A further treatment was also collected, whereby preloaded cells were incubated at 41C for 180 mins. For some experiments, 125 I Ab 1-40 preloaded hCMEC/D3 cells were incubated in fresh culture media containing vinblastine (2 mmol/L), tariquidar (300 nmol/L), FTC (2 mmol/L), or DMSO for 10 mins at 371C. The amount of protein per milligram of total protein was calculated as described above. where 125 I total is the total c.p.m. for the apical and basal compartments, as well as for those remaining in trypsinised cells and inserts. 14 C total is the total inulin disintegrations per minute (d.p.m.) for the apical and basolateral compart-ments. 125 I AP and 14 C AP are the c.p.m. and d.p.m., respectively, in the apical compartment whereas 125 I BL and 14 C BL represent c.p.m. and d.p.m., respectively, in the basolateral compartment.
Statistical Analysis
All data are represented as means ± s.e.m., and the number of experiments, n, indicated each time. For all experiments, a paired Student's t-test was used.
Results

125
I Ab 1-40 Net Uptake by hCMEC/D3 Cells Initially, the net uptake of 0.1 nmol/L 125 I Ab 1-40 was investigated as an indication of all cellular processes regulating Ab 1-40 levels in hCMEC/D3 cells. The Ab 1-40 net uptake refers to all processes that influence Ab 1-40 cellular levels in hCMEC/D3 cells, including those regulating influx (receptormediated internalisation, diffusion, fluid-phase endocytosis, and any 'sticking' to the cell membrane) and efflux (efflux transport, vesicular release, diffusion, and dissociation from the plasma membrane). 125 I Ab 1-40 net uptake by hCMEC/D3 cells was timedependent reaching saturation between 3 and 6 h, with a t 1/2 (time taken to achieve half maximal uptake) of B35 mins ( Figure 1A ). Tariquidar (300 nmol/L), vinblastine (2 mmol/L), and FTC (2 mmol/L) increased the net uptake of 0.1 nmol/L 125 I Ab 1-40 after a 30min incubation by 15%, 8%, and 17% of control levels, respectively. However, only that of tariquidar and vinblastine reached statistical significance (Figure 1B) . These results imply that 125 I Ab 1-40 cellular levels may be influenced by the efflux activity of Pgp, and possibly also that of BCRP.
I Ab 1-40 Efflux from hCMEC/D3 Cells
To further explore the possibility that 125 I Ab 1-40 transport out of hCMEC/D3 cells might be mediated by P-gp or BCRP, we investigated Ab 1-40 efflux from preloaded hCMEC/D3 cells (3 h, 0.1 nmol/L) ( Figure 1C and 1D ). 125 I Ab 1-40 efflux from hCMEC/ D3 cells was time-dependent when compared with maximal cellular Ab 1-40 levels (preloaded cells incubated at 41C), with a t 1/2 of 8.1 ± 1.3 mins, whereas incubation with tariquidar, vinblastine, and FTC increased the t 1/2 by 19.6 ± 5.5%, 19.0 ± 1.0%, and 20.0 ± 0.5%, respectively. After a 10-min incubation at 371C, tariquidar, vinblastine, and FTC increased the cellular levels of 125 I Ab 1-40 by 66%, 49%, and 31%, respectively, compared with control levels. The results indicate that P-gp and BCRP contribute to the efflux of Ab 1-40 from hCMEC/D3 cells.
hCMEC/D3 Cell Permeability to 125 I Ab 1-40
The permeability of hCMEC/D3 cells to Ab 1-40 is a consequence of paracellular diffusion and intracellular processes that include both influx and efflux mechanisms. Therefore, the permeability of hCMEC/ D3 cells grown on inserts to 0.1 nmol/L of 125 I Ab 1-40 in the presence of tariquidar (300 nmol/L), vinblastine (2 mmol/L) and FTC (2 mmol/L), or DMSO control was investigated over a period of 30 mins (Figure 2) . The Ab CQ AP of hCMEC/D3 cells to 125 I Ab 1-40 was increased by 63% with tariquidar (300 nmol/L), 49% with vinblastine (2 mmol/L), and 46% by FTC (2 mmol/L) when compared with control levels. In contrast, the Ab CQ BL was unaltered by tariquidar, vinblastine, or FTC. These results imply that P-gp and BCRP act to prevent the apical-to-basolateral transport of physiologic concentrations of 125 I Ab 1-40. By contrast, P-gp and BCRP may not mediate the Ab basolateral-to-apical transport.
Discussion
The results of this study show that, at physiologic concentrations, P-gp and BCRP inhibition results in an increased net uptake and in a decreased efflux of 125 I Ab 1-40 from hCMEC/D3 cells. Brain endothelial cells express proteins capable of Ab transport into the brain, most notably RAGE and megalin, and out of the brain, namely LRP-1 (Zlokovic, 2008) . Some studies have indicated that P-gp may also influence Ab transcytosis across BECs but, to date, there are no studies investigating the role of P-gp or BCRP in Ab transport by human BECs in vitro. Our results are consistent with earlier in vitro binding data showing possible interactions between P-gp and Ab using nonhuman mammalian cells. Initially, Ab 1-40 and 1-42 were described to compete for the uptake of 3 H-colchicine in Chinese hamster ovary cells overexpressing multi-drug resistance-1 (MDR1) (Lam et al, 2001) and with rhodamine 123 in porcine kidney epithelial cells transfected with human MDR1 (LLC-MDR1 cells) membrane vesicles (Kuhnke et al, 2007) . Furthermore, P-gp inhibitors, cyclosporin A and verapamil, were found to reduce the uptake of fluoresceinisothiocyanate (FITC) conjugated Ab 1-40 and Ab 1-42 in LLC-MDR1 membrane vesicles. We sought to use a more physiologically relevant model of Ab 1-40 transport using human BECs grown on inserts, the results of which indicate that BCRP and P-gp both play a role in preventing the apical-to-basolateral, but not basolateral-to-apical, permeability of hCMEC/D3 cells to 125 I Ab 1-40. Support for the theory that P-gp efflux activity restricts the BBB permeability to Ab has been obtained from cell lines, which are not endothelial in origin and has produced conflicting results. LLC-MDR1 cells have enhanced basolateral-to-apical, but not apical-to-basolateral, permeability to FITC-Ab 1-40/42 (5 mmol/L, 1 h) compared with wild-type LLC cells, which was inhibited by 10 mmol/L of cyclosporin A (Kuhnke et al, 2007) . In contrast, the basolateral-to-apical permeability of MDCK-MDR1 (Madin-Darby canine kidney epithelial cells overexpressing human MDR1) is not increased compared with wild-type MDCK cells after incubation with 1 nmol/L of 125 I Ab 1-40 for 24 and 48 h (Nazer et al, 2008) . These apparently contradicting results may reflect differences in the plasma membrane distribution of efflux transporters between different cultured epithelial cell lines. Although a direct interaction between Ab 1-40 and P-gp or BCRP by, e.g., coimmunoprecipitation techniques remains to be shown, our results using a human BEC line are consistent with a polarised expression of P-gp and BCRP on the apical surface of human cerebral microvessels preventing Ab 1-40 transcytosis (Cooray et al, 2002; Seetharaman et al, 1998) . Interestingly, 125 I Ab 1-40 has been observed to bind to primary human BECs only on the apical membrane and appears to be selectively transported towards the basolateral membrane (Mackic et al, 1998) . However, 65% of the BEC apical binding was found to be attributed to RAGE. It should be noted that astrocytes may influence the polarity of Ab transporters, and that the results from that study were obtained in the absence of astrocytes or astrocyte-conditioned media. In addition, RAGE-Ab interactions are important for the migration of monocytes/macrophages across the BBB (Giri et al, 2000) . Although RAGE might mediate the apical-tobasolateral transport of Ab, our data suggest that P-gp and BCRP on the apical surface of endothelial cells may selectively restrict the apical-to-basolateral permeability of the BBB to Ab 1-40. By contrast, the basolateral-to-apical transport of Ab across BECs, previously shown to be mediated by LRP-1, according to our results, is not affected by P-gp or BCRP inhibition. In vivo, Tg2576 transgenic mice, which harbour the human APP Swedish mutation gene, when treated with a P-gp inhibitor (XR9576) have increased brain interstitial fluid (ISF) levels of Ab (Cirrito et al, 2005) . These results may be on account of a consequence of an increased blood-to-brain Ab transport rather than because of a decreased Ab clearance from the brain. Indeed, the brain efflux of human Ab microinjected intracerebrally was reported to be unaltered in mice treated with P-gp inhibitors, verapamil and quinidine (Ito et al, 2006) . In vivo, the specific contribution of BBB Ab transporters is difficult to interpret as brain resident cells, such as astrocytes (Pardridge et al, 1997) , and cells in the periphery, such as epithelial cells (Schinkel and Jonker, 2003) , are also able to express P-gp. Furthermore, the contribution of P-gp in protecting the brain from plasma Ab species is often overlooked in vivo.
Our in vitro results show that P-gp and BCRP restrict the apical-to-basolateral permeability of hCMEC/D3 cells to Ab 1-40, suggesting a role for these efflux transporters in preventing blood-borne Ab 1-40 from entering the brain, but not in transporting the central nervous system Ab 1-40 into blood. However, in vivo studies need to be carried out to confirm these observations, and also to verify whether other Ab species are transported similarly. Interestingly, the increased plasma levels of Ab are reported in AD patients compared with that in controls by as much as 300% (Lichtlen and Mohajeri, 2008; Sagare et al, 2007) . Therefore, P-gp, and to a lesser extent BCRP, might act to prevent the plasma Ab pool from entering the brain. Many drugs that are in therapeutic use today, such as lipid lowering agents and antidepressants, are transported by P-gp and in principle might act as competitive substrates with Ab for P-gp at the BBB. Therefore, caution should be applied when prescribing drugs, which are P-gp substrates, to AD patients with increased plasma levels of Ab.
